Can Testosterone Be Prescribed in Heart Failure?
Yes, testosterone can be prescribed in patients with heart failure, particularly when documented hypogonadism is present, as the evidence suggests cardiovascular safety and potential functional benefits, though it should not be used in advanced/unstable heart failure or recent cardiovascular events.
FDA-Approved Indications and Warnings
The FDA label for testosterone cypionate specifically indicates use for "replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone" 1. Critically, the FDA warns that "edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal or hepatic disease" 1. This establishes that heart failure is a relative contraindication requiring caution, not an absolute contraindication.
Cardiovascular Safety Profile
The most recent high-quality guideline evidence from the American College of Physicians (2020) provides reassuring data: pooled analysis of 14 trials (n=2,415) showed no significant increase in cardiovascular events with testosterone therapy (Peto OR 1.22, CI 0.66-2.23) 2. The cardiovascular event incidence was 2.3% in testosterone groups versus 1.5% in placebo groups, representing low-certainty evidence but no statistically significant harm 2.
Earlier guideline evidence (2004) from the New England Journal of Medicine concluded that "existing evidence suggests a neutral or possible beneficial effect" of testosterone on cardiovascular disease risk 3. Studies have not demonstrated increased incidence of myocardial infarction, stroke, or angina with testosterone replacement 3.
Clinical Algorithm for Prescribing
Step 1: Confirm Hypogonadism
- Measure morning total testosterone levels (ideally two separate measurements)
- Document symptoms: diminished energy, reduced muscle mass, decreased bone density, sexual dysfunction 3
- Prevalence in heart failure patients: 30-50% have testosterone deficiency; 15% have symptomatic hypogonadism 4
Step 2: Assess Heart Failure Severity
Exclude if:
- Advanced heart failure (NYHA Class IV)
- Recent myocardial infarction or stroke
- Decompensated/unstable heart failure
- Severe fluid retention
Consider treatment if:
- Stable chronic heart failure (NYHA Class II-III)
- Optimized medical therapy already in place
- Documented testosterone deficiency with symptoms
Step 3: Expected Benefits in Heart Failure
Meta-analysis data demonstrates:
- 6-minute walk test improvement: 54.0 meters (95% CI 43.0-65.0m) 5
- Peak oxygen consumption increase: 2.70 mL/kg/min 5
- Improvements in muscle strength and lean muscle mass 6
- Shortened QT interval and improved insulin sensitivity 6
Important caveat: A 2018 randomized trial found no benefit in LVEF, NYHA class, or NT-proBNP levels despite achieving adequate testosterone levels 7. Benefits appear primarily functional rather than affecting cardiac structure or biomarkers.
Monitoring Requirements
Per guideline recommendations 3:
- Hematocrit monitoring (risk of erythrocytosis: 3-18% with transdermal, up to 44% with injections)
- Prostate-specific antigen levels
- Cardiovascular symptoms
- Fluid retention assessment
- Lipid profiles (though most studies show no significant changes)
Formulation Considerations
- Intramuscular injections cause fluctuating levels with "roller coaster" symptom patterns 3
- Transdermal preparations provide more stable levels
- Avoid oral agents due to hepatotoxicity risk 3
Critical Pitfalls to Avoid
- Do not prescribe for athletic performance enhancement - FDA explicitly warns against this 1
- Do not use in acute decompensated heart failure - wait until clinical stability
- Do not ignore baseline cardiovascular risk assessment - most trials excluded recent MI/stroke patients 2
- Do not assume cardiac structural improvement - benefits are primarily functional/symptomatic 7
- Do not neglect prostate monitoring - though prostate cancer risk remains controversial 3
Evidence Quality Considerations
The 2025 systematic review acknowledges that current evidence is limited by small sample sizes and short follow-up periods, with larger event-driven RCTs needed 6. The most methodologically rigorous trial (2018, n=29) showed safety but no significant clinical benefit 7, while meta-analyses suggest functional improvements 5, 8. This divergence suggests benefits may be modest and patient-specific.
The decision ultimately favors cautious use in stable, symptomatic hypogonadal men with chronic heart failure, prioritizing functional capacity improvements while maintaining vigilant cardiovascular monitoring.